{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:02:14Z","timestamp":1769234534253,"version":"3.49.0"},"reference-count":22,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/zelf6405","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:34:40Z","timestamp":1761899680000},"page":"7908-7914","source":"Crossref","is-referenced-by-count":0,"title":["Advanced lung adenocarcinoma with rare EGFR exon 21 T854A mutation: a case report on increased dose osimertinib following resistance"],"prefix":"10.62347","volume":"17","author":[{"given":"Zhihua","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD and Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30.","DOI":"10.3322\/caac.21590"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M. Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to Egfr-Tki therapy in 155 patients with Egfr-mutant lung cancers","volume":"19","author":"HA","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ. Analysis of tumor specimens at the time of acquired resistance to Egfr-Tki therapy in 155 patients with Egfr-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-7.","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","unstructured":"Gainor JF and Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31: 3987-96.","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel third-generation egfr tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","unstructured":"Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, Lippman SM and Husain H. Novel third-generation egfr tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res 2019; 79: 689-98.","journal-title":"Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-08-0151","article-title":"Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854a mutation in a patient with egfr-mutant lung adenocarcinoma","volume":"14","author":"Bean","year":"2008","unstructured":"Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA and Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854a mutation in a patient with egfr-mutant lung adenocarcinoma. Clin Cancer Res 2008; 14: 7519-25.","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"Egfr mutations and resistance to irreversible pyrimidine-based Egfr inhibitors","volume":"21","author":"Ercan","year":"2015","unstructured":"Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS and Jänne PA. Egfr mutations and resistance to irreversible pyrimidine-based Egfr inhibitors. Clin Cancer Res 2015; 21: 3913-23.","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"113523","DOI":"10.1016\/j.ejmech.2021.113523","article-title":"Pyrimidine-based Egfr Tk inhibitors in targeted cancer therapy","volume":"221","author":"Ayati","year":"2021","unstructured":"Ayati A, Moghimi S, Toolabi M and Foroumadi A. Pyrimidine-based Egfr Tk inhibitors in targeted cancer therapy. Eur J Med Chem 2021; 221: 113523.","journal-title":"Eur J Med Chem"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/jccs.202100217","article-title":"Molecular analysis and systematic profiling of allosteric inhibitor response to clinically significant epidermal growth factor receptor missense mutations in non-small cell lung cancer","volume":"68","author":"Zhao","year":"2021","unstructured":"Zhao Y, Zhu D and Gao J. Molecular analysis and systematic profiling of allosteric inhibitor response to clinically significant epidermal growth factor receptor missense mutations in non-small cell lung cancer. J Chin Chem Soc 2021; 68: 2021-34.","journal-title":"J Chin Chem Soc"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Goyal S, Jamal S, Shanker A and Grover A. Structural investigations of T854a mutation in Egfr and identification of novel inhibitors using structure activity relationships. BMC Genomics 2015; 16 Suppl 5: S8.","DOI":"10.1186\/1471-2164-16-S5-S8"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Kohsaka S, Nagano M, Ueno T, Suehara Y, Hayashi T, Shimada N, Takahashi K, Suzuki K, Takamochi K, Takahashi F and Mano H. A method of high-throughput functional evaluation of egfr gene variants of unknown significance in cancer. Sci Transl Med 2017; 9: eaan6566.","DOI":"10.1126\/scitranslmed.aan6566"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.21037\/jtd-19-3790","article-title":"Uncommon Egfr mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors","volume":"12","author":"Brindel","year":"2020","unstructured":"Brindel A, Althakfi W, Barritault M, Watkin E, Maury JM, Bringuier PP, Girard N and Brevet M. Uncommon Egfr mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors. J Thorac Dis 2020; 12: 4643-4650.","journal-title":"J Thorac Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1634\/theoncologist.2015-0073","article-title":"Afatinib in non-small cell lung cancer harboring uncommon Egfr mutations pretreated with reversible Egfr inhibitors","volume":"20","author":"DF","year":"2015","unstructured":"Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F and Scheffler M; Afatinib Compassionate Use Consortium (ACUC). Afatinib in non-small cell lung cancer harboring uncommon Egfr mutations pretreated with reversible Egfr inhibitors. Oncologist 2015; 20: 1167-74.","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jtho.2018.04.005","article-title":"Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment","volume":"13","author":"Uchibori","year":"2018","unstructured":"Uchibori K, Inase N, Nishio M, Fujita N and Katayama R. Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment. J Thorac Oncol 2018; 13: 915-25.","journal-title":"J Thorac Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12885-017-3263-z","article-title":"Efficacy of irreversible Egfr-Tkis for the uncommon secondary resistant Egfr mutations L747s, D761y, and T854a","volume":"17","author":"Chiba","year":"2017","unstructured":"Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T and Nishio K. Efficacy of irreversible Egfr-Tkis for the uncommon secondary resistant Egfr mutations L747s, D761y, and T854a. BMC Cancer 2017; 17: 281.","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cllc.2021.12.008","article-title":"Molecular characteristics of the uncommon Egfr exon 21 T854a mutation and response to osimertinib in patients with non-small cell lung cancer","volume":"23","author":"Zhang","year":"2022","unstructured":"Zhang L, Yang X, Ming Z, Shi J, Lv X, Li W, Yuan B, Chen Y, Liu B, Qin K, Liu J, Wei Q, Gu D, Chen R, Yuan M, Cui J, Ou SI and Yang S. Molecular characteristics of the uncommon Egfr exon 21 T854a mutation and response to osimertinib in patients with non-small cell lung cancer. Clin Lung Cancer 2022; 23: 311-9.","journal-title":"Clin Lung Cancer"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M and Engelman JA. Genotypic and histological evolution of lung cancers acquiring resistance to Egfr inhibitors. Sci Transl Med 2011; 3: 75ra26.","DOI":"10.1126\/scitranslmed.3002003"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced ret-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","unstructured":"Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M and Kris MG. Cabozantinib in patients with advanced ret-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol 2016; 17: 1653-60.","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Zhao N, Xin H, Qin C, Li Z and Sun H. Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon Egfr T854a mutation: a case report. Medicine (Baltimore) 2022; 101: e31875.","DOI":"10.1097\/MD.0000000000031875"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","unstructured":"Gainor JF and Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31: 3987-96.","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12943-022-01534-8","article-title":"Integration of liquid biopsy and pharmacogenomics for precision therapy of Egfr mutant and resistant lung cancers","volume":"21","author":"Kolesar","year":"2022","unstructured":"Kolesar J, Peh S, Thomas L, Baburaj G, Mukherjee N, Kantamneni R, Lewis S, Pai A, Udupa KS, Kumar An N, Rangnekar VM and Rao M. Integration of liquid biopsy and pharmacogenomics for precision therapy of Egfr mutant and resistant lung cancers. Mol Cancer 2022; 21: 61.","journal-title":"Mol Cancer"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0156783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T01:54:37Z","timestamp":1769133277000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0156783.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/zelf6405","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}